Download PDF
Semin Thromb Hemost 2006; 32(7): 700-708
DOI: 10.1055/s-2006-951298
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Inherited Thrombophilia and Venous Thromboembolism

Paolo Simioni1 , Daniela Tormene1 , Luca Spiezia1 , Giulio Tognin1 , Valeria Rossetto1 , Claudia Radu1 , Paolo Prandoni1
  • 1Department of Medical and Surgical Sciences, University of Padua, Medical School, Padua, Italy
Further Information

Publication History

Publication Date:
06 October 2006 (online)

    Permissions and Reprints

ABSTRACT

The term thrombophilia includes any inherited and acquired disorders associated with an increased tendency to venous thromboembolism (VTE). Inherited thrombophilia is one of the main determinants of VTE, and the presence of inherited thrombophilic defects exposed carriers to increased risks for VTE compared with noncarriers. There is no clear relationship between clinical manifestations and the type of underlying thrombophilic defect. Thus, the diagnosis of inherited thrombophilia has to be established on a laboratory basis. Carriers of thrombophilic defects may experience thrombosis at a younger age than noncarriers. However, a first thrombotic manifestation that occurs late in life may also be an expression of thrombophilia and this remains in many cases the only etiopathogenetic explanation for the event. Screening of family members of symptomatic probands has the potential to identify still asymptomatic carriers who may benefit from more appropriate thromboprophylaxis during high-risk situations for VTE. Women of fertile age who belong to these thrombophilic families might receive the greatest advantage from screening. Many inherited thrombophilic disorders can be considered risk factors for recurrent VTE, especially if more than one defect is present in the same patient. More intensive or prolonged duration of VTE treatment might be requested for the prevention of recurrent VTE in the most severe thrombophilic conditions. The availability of new methods for the assessment of thrombin generation in terms of endogenous thrombin potential are very promising tools for the identification of those carriers of inherited thrombophilia who will develop thrombosis or who will encounter recurrence of VTE.

KEYWORDS

Inherited thrombophilia - genetic defects - acquired risk factors - recurrent venous thromboembolism (VTE) - laboratory screening - prophylaxis of VTE

REFERENCES

  • 1 Egeberg O. Inherited antithrombin deficiency causing thrombophilia.  Thromb Diath Haemorrh. 1965;  13 516-530
    PubMedGoogle Scholar
  • 2 Prandoni P, Bilora F, Marchiori A et al.. An association between atherosclerosis and venous thrombosis.  N Engl J Med. 2003;  348 1435-1441
    CrossrefPubMedGoogle Scholar
  • 3 Koeleman B P, Reitsma P H, Allaart C F, Bertina R M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.  Blood. 1994;  84 1031-1035
    PubMedGoogle Scholar
  • 4 van Boven H H, Reitsma P H, Rosendaal F R et al.. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.  Thromb Haemost. 1996;  75 417-421
    PubMedGoogle Scholar
  • 5 Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.  Blood. 1995;  85 3518-3523
    PubMedGoogle Scholar
  • 6 Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation. 1995;  92 2800-2802
    CrossrefPubMedGoogle Scholar
  • 7 Simioni P, Prandoni P, Lensing A W et al.. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med. 1997;  336 399-403
    CrossrefPubMedGoogle Scholar
  • 8 Simioni P, Prandoni P, Lensing A W et al.. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.  Blood. 2000;  96 3329-3333
    PubMedGoogle Scholar
  • 9 Miles J S, Miletich J P, Goldhaber S Z, Hennekens C H, Ridker P M. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.  J Am Coll Cardiol. 2001;  37 215-218
    CrossrefPubMedGoogle Scholar
  • 10 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med. 1999;  341 801-806
    CrossrefPubMedGoogle Scholar
  • 11 Eichinger S, Pabinger I, Stumpflen A et al.. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.  Thromb Haemost. 1997;  77 624-628
    PubMedGoogle Scholar
  • 12 Eichinger S, Minar E, Hirschl M et al.. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.  Thromb Haemost. 1999;  81 14-17
    PubMedGoogle Scholar
  • 13 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group Duration of Anticoagulation.  Thromb Haemost. 1999;  81 684-689
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kearon C, Gent M, Hirsh J et al.. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med. 1999;  340 901-907
    PubMedGoogle Scholar
  • 15 Margaglione M, D'Andrea G, Colaiazzo D et al.. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism.  Thromb Haemost. 1999;  82 1583-1587
    PubMedGoogle Scholar
  • 16 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.  Br J Haematol. 2001;  113 630-635
    CrossrefPubMedGoogle Scholar
  • 17 Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa?.  J Thromb Haemost. 2003;  1 16-18
    CrossrefPubMedGoogle Scholar
  • 18 Christiansen S C, Cannegieter S C, Koster T, Vandenbroucke J P, Rosendaal F R. Thrombophilia, clinical factors, and recurrent venous thrombotic events.  JAMA. 2005;  293 2352-2361
    CrossrefPubMedGoogle Scholar
  • 19 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.  Lancet. 2003;  362 523-526
    CrossrefPubMedGoogle Scholar
  • 20 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202
    PubMedGoogle Scholar
  • 21 Lane D A, Olds R J, Boisclair M et al.. Antithrombin III mutation database: first update.  Thromb Haemost. 1993;  70 361-369
    PubMedGoogle Scholar
  • 22 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.  Blood. 1998;  92 2353-2358
    PubMedGoogle Scholar
  • 23 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases.  Thromb Haemost. 1987;  58 1094 (letter)
    PubMedGoogle Scholar
  • 24 Vasse M, Borg J Y, Monconduit M. Protein C: Rouen, a new hereditary protein C abnormality with low anticoagulant but normal amidolytic activities.  Thromb Res. 1989;  56 387-398
    CrossrefPubMedGoogle Scholar
  • 25 Mimuro J, Muramatsu S, Kaneko M et al.. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG→GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency.  Int J Hematol. 1993;  57 9-14
    PubMedGoogle Scholar
  • 26 Girolami A, Simioni P, Girolami B et al.. A novel dysfunctional protein C (protein C Padua 2) associated with a thrombotic tendency: substitution of Cys for Arg-1 results in a strongly reduced affinity for binding of Ca ++ .  Br J Haematol. 1993;  85 521-527
    PubMedGoogle Scholar
  • 27 Gandrille S, Alhenc-Gelas M, Gaussem P et al.. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity.  Blood. 1993;  82 159-168
    PubMedGoogle Scholar
  • 28 Wojcik E G, Simioni P, van den Berg M, Girolami A, Bertina R M. Mutations which introduce free cysteine residues in the Gla-domain of vitamin K dependent proteins result in the formation of complexes with alpha 1-microglobulin.  Thromb Haemost. 1996;  75 70-75
    PubMedGoogle Scholar
  • 29 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med. 1984;  311 1525-1528
    CrossrefPubMedGoogle Scholar
  • 30 Schwarz H P, Fischer M, Hopmeier P, Batard M A, Griffin J H. Plasma protein S deficiency in familial thrombotic disease.  Blood. 1984;  64 1297-1300
    PubMedGoogle Scholar
  • 31 Gandrille S, Borgel D, Ireland H et al.. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1997;  77 1201-1214
    PubMedGoogle Scholar
  • 32 Faioni E M, Boyer-Neumann C, Franchi F, Wolf M, Meyer D, Mannucci P M. Another protein S functional assay is sensitive to resistance to activated protein C.  Thromb Haemost. 1994;  72 648 (letter)
    PubMedGoogle Scholar
  • 33 Simioni P, Gavasso S, Luni S, Invidiato S, Girolami A. A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance.  Blood Coagul Fibrinolysis. 1995;  6 286-287
    PubMedGoogle Scholar
  • 34 Faioni E M, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci P M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.  Thromb Haemost. 1993;  70 1067-1071
    PubMedGoogle Scholar
  • 35 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet. 1995;  346 1133-1134
    CrossrefPubMedGoogle Scholar
  • 36 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden.  Blood. 1995;  85 1504-1508
    PubMedGoogle Scholar
  • 37 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature. 1994;  369 64-67
    CrossrefPubMedGoogle Scholar
  • 38 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C.  Blood. 1998;  91 1140-1144
    PubMedGoogle Scholar
  • 39 Simioni P, Kalafatis M, Manfrin D, Tormene D, Girolami A. Factor V variants, activated protein C resistance and venous thromboembolism.  Blood Coagul Fibrinolysis. 1998;  9 661-662
    PubMedGoogle Scholar
  • 40 Bernardi F, Faioni E M, Castoldi E et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.  Blood. 1997;  90 1552-1557
    PubMedGoogle Scholar
  • 41 Chan W P, Lee C K, Kwong Y L, Lam C K, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.  Blood. 1998;  91 1135-1139
    PubMedGoogle Scholar
  • 42 de Visser M C, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood. 1999;  93 1271-1276
    PubMedGoogle Scholar
  • 43 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
    CrossrefPubMedGoogle Scholar
  • 44 Makris M, Preston F E, Beauchamp N J et al.. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia.  Thromb Haemost. 1997;  78 1426-1429
    PubMedGoogle Scholar
  • 45 Rosendaal F R, Doggen C J, Zivelin A et al.. Geographic distribution of the 20210 G to A prothrombin variant.  Thromb Haemost. 1998;  79 706-708
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost. 1999;  81 165-176
    PubMedGoogle Scholar
  • 47 Guba S C, Fonseca V, Fink L M. Hyperhomocysteinemia and thrombosis.  Semin Thromb Hemost. 1999;  25 291-309
    PubMedGoogle Scholar
  • 48 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.  Lancet. 1995;  345 152-155
    CrossrefPubMedGoogle Scholar
  • 49 Bank I, Libourel E J, Middeldorp S et al.. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis.  J Thromb Haemost. 2005;  3 79-84
    CrossrefPubMedGoogle Scholar
  • 50 van der Meer F J, Koster T, Vandenbroucke J P, Briet E, Rosendaal F R. The Leiden Thrombophilia Study (LETS).  Thromb Haemost. 1997;  78 631-635
    PubMedGoogle Scholar
  • 51 Cushman M, Tsai A W, White R H et al.. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.  Am J Med. 2004;  117 19-25
    CrossrefPubMedGoogle Scholar
  • 52 Tsai A W, Cushman M, Rosamond W D et al.. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).  Am J Med. 2002;  113 636-642
    CrossrefPubMedGoogle Scholar
  • 53 Vandenbroucke J P, Koster T, Briet E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.  Lancet. 1994;  344 1453-1457
    CrossrefPubMedGoogle Scholar
  • 54 Tormene D, Fortuna S, Tognin G et al.. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study.  J Thromb Haemost. 2005;  3 1414-1420
    CrossrefPubMedGoogle Scholar
  • 55 van't Veer C, Golden N J, Kalafatis M, Simioni P, Bertina R M, Mann K G. An in vitro analysis of the combination of hemophilia A and factor V (Leiden).  Blood. 1997;  90 3067-3072
    PubMedGoogle Scholar
  • 56 van Dijk K, van der Bom J G, Fischer K, Grobbee D E, van den Berg H M. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature.  Thromb Haemost. 2004;  92 305-310
    PubMedGoogle Scholar
  • 57 Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: an unexpected association!.  Haemophilia. 2004;  10 319-326
    CrossrefPubMedGoogle Scholar
  • 58 Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency.  Blood. 2005;  106 2363-2365
    CrossrefPubMedGoogle Scholar
  • 59 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 338S-400S
    CrossrefPubMedGoogle Scholar
  • 60 Büller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 401S-428S
    CrossrefPubMedGoogle Scholar
  • 61 Sanson B J, Simioni P, Tormene D et al.. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study.  Blood. 1999;  94 3702-3706
    PubMedGoogle Scholar
  • 62 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Fallon W M, Melton III L J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.  Arch Intern Med. 2000;  160 761-768
    CrossrefPubMedGoogle Scholar
  • 63 Kyrle P A, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women.  N Engl J Med. 2004;  350 2558-2563
    CrossrefPubMedGoogle Scholar
  • 64 Prandoni P, Lensing A W, Prins M H et al.. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism.  Ann Intern Med. 2002;  137 955-960
    PubMedGoogle Scholar
  • 65 Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden-cost-effectiveness analysis.  Thromb Haemost. 2000;  84 752-757
    PubMedGoogle Scholar
  • 66 Tormene D, Simioni P, Prandoni P et al.. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study.  Blood. 2002;  100 2403-2405
    CrossrefPubMedGoogle Scholar
  • 67 Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia.  Semin Thromb Hemost. 2005;  31 25-32
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Palareti G, Legnani C, Cosmi B et al.. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.  Circulation. 2003;  108 313-318
    CrossrefPubMedGoogle Scholar
  • 69 Sere K M, Rosing J, Hackeng T M. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance.  Blood. 2004;  104 3624-3630
    CrossrefPubMedGoogle Scholar
  • 70 Curvers J, Thomassen M C, Rimmer J et al.. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.  Thromb Haemost. 2002;  88 5-11
    PubMedGoogle Scholar
  • 71 Middeldorp S, Meinardi J R, Koopman M M et al.. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.  Ann Intern Med. 2001;  135 322-327
    CrossrefPubMedGoogle Scholar
  • 72 Simioni P, Prandoni P, Girolami A. Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation.  Ann Intern Med. 1999;  130 538 (letter)
    PubMedGoogle Scholar
  • 73 De Stefano V, Leone G, Mastrangelo S et al.. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S.  Thromb Haemost. 1994;  72 352-358
    PubMedGoogle Scholar
  • 74 Tormene D, Simioni P, Pagnan A, Prandoni P. The G20210A prothrombin gene mutation: is there room for screening families?.  J Thromb Haemost. 2004;  2 1487-1488
    CrossrefPubMedGoogle Scholar

 Prof.
Paolo SimioniM.D. Ph.D. 

Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School

via Ospedale 105, 35100 Padua, Italy

Email: paolo.simioni@unipd.it

      >